The Landscape of Targeted Therapies in TNBC

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exploring and comparing adverse events between PARP inhibitors

(2019) Christopher J LaFargue et al.   LANCET ONCOLOGY

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

(2019) M E Robson et al.   ANNALS OF ONCOLOGY

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

(2019) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

(2019) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA repair in cancer initiation, progression, and therapy—a double-edged sword

(2019) Katarzyna Kiwerska et al.   JOURNAL OF APPLIED GENETICS

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

(2019) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing

(2018) Charissa Kim et al.   CELL

Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas

(2018) Yue Bi et al.   GYNECOLOGIC ONCOLOGY

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer

(2018) Marni B. Siegel et al.   JOURNAL OF CLINICAL INVESTIGATION

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

(2018) Tiffany A. Traina et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

(2018) Theo A. Knijnenburg et al.   Cell Reports

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).

(2018) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

(2018) S Loibl et al.   ANNALS OF ONCOLOGY

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Liquid Biopsies

(2018) Evi Lianidou et al.   GENES CHROMOSOMES & CANCER

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

(2018) Todd A. Hopkins et al.   MOLECULAR CANCER RESEARCH

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel inBRCA1/2metastatic breast cancer: design and rationale

(2017) Steven J Isakoff et al.   Future Oncology

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Sung-Bae Kim et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Poly(ADP-ribose) polymerase activity and inhibition in cancer

(2017) Caleb Dulaney et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases

(2017) Helen Ha et al.   Theranostics

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

(2017) Eric Hahnen et al.   JAMA Oncology

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

(2017) H. D. Bear et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)

(2016) M. Martín et al.   ANNALS OF ONCOLOGY

Biomarkers associated with checkpoint inhibitors

(2016) G. Manson et al.   ANNALS OF ONCOLOGY

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

(2016) H. Bonnefoi et al.   ANNALS OF ONCOLOGY

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

(2016) Erik Hilborn et al.   BRITISH JOURNAL OF CANCER

Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer

(2016) Yuka Asano et al.   BRITISH JOURNAL OF CANCER

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

(2016) Luca Gianni et al.   LANCET ONCOLOGY

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

(2016) Hope S. Rugo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

(2016) Bernard Pereira et al.   Nature Communications

Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis

(2016) Changjun Wang et al.   Oncotarget

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

(2016) Pin Zhang et al.   Oncotarget

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

(2016) Brian D. Lehmann et al.   PLoS One

Racial/Ethnic and Socioeconomic Differences in Short-Term Breast Cancer Survival Among Women in an Integrated Health System

(2015) Theresa H. M. Keegan et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer

(2015) Jing Huang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

(2015) J. Zaragoza et al.   BRITISH JOURNAL OF DERMATOLOGY

Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis

(2015) Yoonseok Kim et al.   Journal of Breast Cancer

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2014) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†

(2014) A. M. Gonzalez-Angulo et al.   ANNALS OF ONCOLOGY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†

(2014) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis

(2014) Fausto Petrelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

(2014) T. Byrski et al.   BREAST CANCER RESEARCH AND TREATMENT

DNA breaks and chromosomal aberrations arise when replication meets base excision repair

(2014) Michael Ensminger et al.   JOURNAL OF CELL BIOLOGY

Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

(2014) John M. Lambert et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Transcriptional Roles of PARP1 in Cancer

(2014) Matthew J. Schiewer et al.   MOLECULAR CANCER RESEARCH

PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair

(2014) Y. Hu et al.   Cancer Discovery

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

(2013) Judith Michels et al.   CELL CYCLE

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Beyond DNA repair, the immunological role of PARP-1 and its siblings

(2013) Maria Manuela Rosado et al.   IMMUNOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art

(2012) Mike De Vos et al.   BIOCHEMICAL PHARMACOLOGY

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

(2012) E. Alba et al.   BREAST CANCER RESEARCH AND TREATMENT

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms

(2012) J. K. Singh et al.   CLINICAL CANCER RESEARCH

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

(2012) Bryan A. Gibson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator

(2012) Federica Laudisi et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group

(2011) K. D. Miller et al.   ANNALS OF ONCOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

(2011) D. G. Evans et al.   JOURNAL OF MEDICAL GENETICS

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Biomarkers for Basal-like Breast Cancer

(2010) Jennifer R. Choo et al.   Cancers

Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms

(2009) Enrico Ruffini et al.   ANNALS OF THORACIC SURGERY

Homologous recombination in DNA repair and DNA damage tolerance

(2008) Xuan Li et al.   CELL RESEARCH

The Interleukin-8 Pathway in Cancer

(2008) D. J.J. Waugh et al.   CLINICAL CANCER RESEARCH

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of DNA repair genes is associated with metastasis: A new hypothesis

(2008) A SARASIN et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH